A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
Fukui T, Mamesaya N, Takahashi T, Kishi K, Yoshizawa T, Tokito T, Azuma K, Morikawa K, Igawa S, Okuma Y, Yamanaka Y, Hosokawa S, Kasai T, Masubuchi K, Nakamichi S, Aga M, Sasaki J, Kada A, Saito AM, Naoki K, Okamoto H; Thoracic Oncology Research Group (TORG).
Fukui T, et al. Among authors: takahashi t.
J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548-6. doi: 10.1016/j.jtho.2024.12.027. Online ahead of print.
J Thorac Oncol. 2025.
PMID: 39755169